BioReagent 级 ，适用于对基线干扰要求严格的色谱和分析工作流程。
2-8°C储存。低温运输 。请查阅批次 COA 获取详细规格。
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
Labetuzumab是一种用于治疗结直肠癌的人源化 IgG1 单克隆抗体，具有抗癌活性，属于靶向治疗药物。其通过特异性结合癌胚抗原，抑制肿瘤细胞生长，主要用于结直肠癌和甲状腺癌的研究与治疗。拉贝珠单抗还能增强肿瘤细胞对化疗药物（如达卡巴嗪）的敏感性，为联合治疗提供了新策略。 本试剂盒采用间接法酶联免疫吸附试验（ELISA）。往预先包被有人CEACA5抗原的微孔中，依次加入样本、标准品、HRP标记的二抗，中间经过温育和洗涤，用底物TMB显色，TMB在过氧化物酶(HRP)的催化下转化成蓝色，并在酸的作用下转化成最终的黄色。颜色的深浅和样本中的拉贝珠单抗(Labetuzumab)呈正相关。用酶标仪在450nm波长下测定吸光度（OD值），计算样本浓度。
This kit employs the indirect enzyme-linked immunosorbent assay (ELISA) principle. Microplate wells are pre-coated with Human CEACA5 antigen. The sample or standard is first added to the wells, followed by an HRP (horseradish peroxidase)-labeled secondary antibody. The procedure involves incubation and wash steps between each addition. TMB substrate is then added for color development. Under the catalysis of the peroxidase (HRP), TMB is converted into a blue product, which subsequently turns into a final stable yellow color upon the addition of an acid stop solution. The intensity of the yellow color is directly proportional to the concentration of Labetuzumab in the sample. The optical density (OD) is measured at a wavelength of 450 nm using a microplate reader, and the concentration of the target analyte in the sample is calculated based on the standard curve.
危险品化学品经营许可证（带存储）